TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
NextCell Pharma AB
Closing information (x1000 NOK)
| Closing information | 2024/08 | 2023/08 | 2022/08 |
| Turnover |
10,972
|
9,863
|
5,141 |
| Financial expenses |
1
|
3
|
13 |
| Earnings before taxes |
-43,169
|
-38,828
|
-31,783 |
| EBITDA |
-43,412
|
-39,552
|
-31,794 |
| Total assets |
83,629
|
86,632
|
114,657 |
| Current assets |
62,371
|
65,610
|
98,192 |
| Current liabilities |
10,157
|
9,831
|
6,376 |
| Equity capital |
69,546
|
73,855
|
106,272 |
| - share capital |
15,416
|
6,874
|
6,483 |
| Employees (average) |
24
|
17
|
15 |
Financial ratios
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Solvency |
83.2%
|
85.3%
|
92.7% |
| Turnover per employee |
457
|
580
|
343 |
| Profit as a percentage of turnover |
-393.4%
|
-393.7%
|
-618.2% |
| Return on assets (ROA) |
-51.6%
|
-44.8%
|
-27.7% |
| Current ratio |
614.1%
|
667.4%
|
1540.0% |
| Return on equity (ROE) |
-62.1%
|
-52.6%
|
-29.9% |
| Change turnover |
568
|
4,412
|
1,542 |
| Change turnover % |
5%
|
81%
|
43% |
| Chg. No. of employees |
7
|
2
|
2 |
| Chg. No. of employees % |
41%
|
13%
|
15% |
Total value of public sale
| Fiscal year | 2024/08 | 2023/08 | 2022/08 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.